Daewoong Pharma: supply contract with Abbott Products terminated

Daewoong Pharma · KOSPI · 069620 · Nov 2, 2026 · Supply contracts

Daewoong Pharma reported the termination of a supply contract with ABBOTT PRODUCTS OPERATIONS AG (Switzerland), with a contract amount of ₩69.2bn. The filing states the amount as 8.2% of revenue. The termination date was Feb 28, 2024.

Key facts

EventContract terminated
CounterpartyABBOTT PRODUCTS OPERATIONS AG (Switzerland)
Terminated contract amount₩69.2bn
% of revenue (as reported)8.2%
Termination dateFeb 28, 2024

Comparison

Amount as % of FY2025 revenue (calculated)4.4%
Revenue 2025₩1.6tn
Revenue 2024₩1.4tn
Revenue 2023₩1.4tn

Context

In the 12 months before this filing, the company filed 1 supply contract disclosure, with a total of ₩92.6bn.

Key metrics

Supply contracts

Supply contracts, last 12 months₩92.6bn As of Jun 26, 2026 Source 1 ↗
Supply contracts vs prior-year revenue5.9% As of Jun 26, 2026 Source 1 ↗
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Source: DART (Financial Supervisory Service) · Original filing on DART ↗ (opens the Financial Supervisory Service's DART site)